Focused On-demand Library for Cytokine receptor common subunit beta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P32927

UPID:

IL3RB_HUMAN

Alternative names:

CDw131; GM-CSF/IL-3/IL-5 receptor common beta subunit

Alternative UPACC:

P32927; Q5JZI1; Q6ICE0

Background:

The Cytokine receptor common subunit beta, known as CDw131 or GM-CSF/IL-3/IL-5 receptor common beta subunit, plays a pivotal role in immune response. It controls the production and differentiation of hematopoietic progenitor cells into specific lineages by forming heterodimeric receptors with partners like IL3RA, IL5RA, or CSF2RA. This interaction activates various signaling pathways, including the JAK-STAT pathway, crucial for immune response and cell differentiation.

Therapeutic significance:

Linked to Pulmonary surfactant metabolism dysfunction 5, a rare lung disorder, the Cytokine receptor common subunit beta's understanding could unveil new therapeutic strategies. Its role in immune response and cell differentiation pathways highlights its potential as a target for treating this and possibly other immune-related diseases.